Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)-
Unresectable Solid Tumor
Relay Therapeutics, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Unresectable Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[177lu]lu-sn201 Spago Nanomedical AB | Phase 1/2 | CC |
Fmc-376 Frontier Medicines Corporation | Phase 1/2 | CC |
Mdna11 Medicenna Therapeutics, Inc. | Phase 1/2 | CC |
Pembrolizumab Medicenna Therapeutics, Inc. | Phase 1/2 | CC |
rc118 RemeGen Co., Ltd. | Phase 1 | CC |
View all 20 →
Same molecule, other indications
Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →